Clin2Atlas
AtlasBrain & nervesNeurological disorders

Motor neuron disease

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251995 — Riluzole approved (FDA)2017 — Edaravone approved (FDA)2020 — Risdiplam approved (FDA)2020 — Onasemnogene abeparvovec approved (FDA)2023 — Tofersen approved (FDA)
1995: Drug approval — Riluzole approved (FDA). 2017: Drug approval — Edaravone approved (FDA). 2020: Drug approval — Risdiplam approved (FDA). 2020: Drug approval — Onasemnogene abeparvovec approved (FDA). 2023: Drug approval — Tofersen approved (FDA)

What's being tested now

2000: 1 trials started2005: 1 trials started2006: 3 trials started2007: 3 trials started2008: 3 trials started2009: 2 trials started2010: 2 trials started2011: 1 trials started2013: 3 trials started2014: 1 trials started2015: 5 trials started2016: 2 trials started2017: 8 trials started2018: 5 trials started2019: 10 trials started2020: 11 trials started2021: 18 trials started2022: 16 trials started2023: 31 trials started2024: 65 trials started2025: 95 trials started2026: 88 trials started200020102020202695

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 353 active Amyotrophic Lateral Sclerosis trials on Clin2 →

Related

Alzheimer's disease and other dementiasParkinson's diseaseIdiopathic epilepsyMultiple sclerosisOther neurological disorders

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.